Oppenheimer maintains Corpay at Outperform, raises price target to $461 from $454

Oppenheimer kept its Outperform rating on Corpay and increased its price target to $461 from $454, suggesting a 10.1% upside from the Nov 4 close of $418.60, according to the firm.

Original reporting
Published Nov 5, 2026, 5:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 5:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer maintains Corpay at Outperform, raises price target to $461 from $454 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The rating upgrade suggests a slight bullish bias but does not constitute a major catalyst.

02

Market read

A modest analyst target increase provides a small positive signal for traders, but limited actionable impact.

03

What to watch

Potential upcoming earnings or macro trends could outweigh the rating change.

Relevance 6/10Novelty 5/10Timing: today

Background

Oppenheimer raised its price target for Corpay from $454 to $461, implying a 10.1% upside from the prior close.

Market effects

Analyst upgrade may lift sentiment in the fintech payments sector.

Limited to U.S. markets where the stock trades.

Minimal global impact.

Counterpoint

The modest target raise may already be priced in; investors could wait for further catalyst.

Key entities

  • Corpay

    Fintech payments provider subject of the rating change.

  • Oppenheimer

    Issued the upgraded price target.

Related articles

$CPAYMed

What Corpay (CPAY) Said on Its Q3 Earnings Call

Corpay (CPAY) reported Q3 gross margin at 30.4%, up from Q2 but down annually. Cash position was CAD 50.6M. Acquired AISPECO for airborne sensors. Expects revenue synergies sooner. Plans to scale manufacturing and expand commercial/defense businesses. Corpay provides corporate payment solutions.

$CPAYMedAI 8/10

Corpay 3Q 2026: Revenue $1.38B, EPS $5.66 — 10-Q Summary

Corpay reported 3Q 2026 revenue of $1.38B, up 17.9% YoY, and net income of $378.42M, up 36.2% YoY. Growth was driven by organic spend and transaction volumes, new sales, and acquisitions. Higher operating expenses and other costs partly offset gains. Management expects liquidity to meet needs for the next 12 months.

$CPAYHighAI 8/10

Corpay (CPAY) Q3 2026 Earnings Call Transcript

Corpay (CPAY) raised Q4 2026 revenue guidance to $1.37B and cash EPS to $7.65, up 27%. Full-year 2026 revenue is expected to rise 18%, with cash EPS up over 30%. For 2027, Corpay anticipates 9-11% organic revenue growth. The company has divested noncore businesses, using proceeds for share buybacks, and plans to allocate $2B in free cash flow to acquisitions or buybacks. Corporate Payments segment growth is expected to remain in the high teens.

$CPAYMed

Corpay Q3 Earnings Call Highlights

Corpay (NYSE:CPAY) expects 9-11% organic revenue growth in 2027, with $2B in free cash flow for acquisitions or share repurchases. The company divested noncore businesses in 2026, using proceeds for buybacks. Alpha and Avid are expected to contribute over $1.40 in combined cash EPS accretion in 2026. Corpay aims to compound adjusted EPS by over 20% annually through 2029.

$CPAYMed

Corpay Inc (CPAY) (Q3 2026) Earnings Call Highlights: Sixth Straight Quarter

Corpay Inc (CPAY) reported Q3 2026 earnings, guiding Q4 organic revenue growth at 10%, slightly below Q3's 11%. Corporate payments growth is ~17% excluding one-time items, while lodging and vehicle payments show mixed results. The company may pursue divestitures and is uncertain about acquiring the remaining stake in Avid. Operating costs rose 9%, and tax rate decreased to 23.4%. CEO Ronald Clarke highlighted strong corporate payments growth and potential for 2027.